JOEL S MARCUS
CIK 1216955 · Executive Chairman · last filed 2026-05-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$54.94M
Companies
8
Total Filings
287
Lifetime Open-Market Net
-$156.07M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARE | Executive Chairman | 587,724 | $48.35 | $28.42M | -$139.75M | 193 | 2026-05-07 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | Director | 0 | $131.87 | $0 | -$13.07M | 43 | 2025-04-02 |
| Applied Therapeutics, Inc. (APLT) Delisted | Director | 565,849 | $0.10 | $58.3K | -$257.6K | 15 | 2024-06-07 |
| Korro Bio, Inc. (FREQ) Delisted | Director | 26,377 | $14.98 | $395.1K | -$1.32M | 11 | 2022-08-19 |
| MGTX | Director | 1,995,608 | $13.02 | $25.98M | -$294.2K | 7 | 2022-06-09 |
| ATRA | Director | 460 | $8.61 | $4.0K | -$1.52M | 12 | 2019-03-19 |
| REXR | Director | 12,858 | $36.47 | $468.9K | $140.0K | 1 | 2013-07-24 |
| PMT | Director | 7,000 | $9.38 | $65.7K | $0 | 2 | 2012-05-18 |
Recent Filings · Page 3 of 29
287 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-09 | ARE | Grant (A) | +3,000 | $0 | EDGAR |
| 2024-01-04 | ARE | Grant (A) | +47,620 | $0 | EDGAR |
| 2023-09-19 | Applied Therapeutics, Inc. (APLT) Delisted | Exer (M) | +12,375 | $13.0K | EDGAR |
| 2023-06-27 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | Applied Therapeutics, Inc. (APLT) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2023-05-10 | ARE | Sell (S) | −7,500 | -$916.5K | EDGAR |
| 2023-05-08 | ARE | Notice (144) | −9,500 | -$1.16M | EDGAR |
| 2023-04-04 | ARE | Mixed | −16,522 | -$1.26M | EDGAR |
| 2023-02-09 | ARE | Sell (S) | −9,000 | -$1.51M | EDGAR |
| 2023-01-31 | ARE | Tax (F) | −5,608 | -$901.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.